Press Releases

Everest Medicines Announces Amended Agreement with Spero Therapeutics

Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration for Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer

Everest Medicines Initiates Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer

Everest Medicines Appoints Lan Kang to Board of Directors

Everest Medicines Announces First Patient Dosed in Phase 3 Registration Asian Study of Trodelvy™ (sacituzumab govitecan) for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Everest Medicines Announces The China Center for Drug Evaluation, National Medical Products Administration Recommends Breakthrough Therapy Designation for Nefecon for the Treatment of IgA Nephropathy

Everest Medicines Announces that Licensing Partner Calliditas Therapeutics has Reported Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Everest Medicines Announces First Patient Dosed in its Phase 2b Registration Clinical Trial of Trodelvy™ (sacituzumab govitecan) for Metastatic Triple-Negative Breast Cancer in China

Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration for Phase 3 Registration Trial of Trodelvy™ for Metastatic Breast Cancer in China

Everest Medicines Announces the Offer Price and Allotment Results of the Global Offering

Everest Medicines Announced Its Global Offering and Proposed Listing on the Stock Exchange of Hong Kong

Everest Medicines Announces Top-line Results from Phase 1 Clinical Trial of Taniborbactam in Combination with Cefepime in China

Everest Medicines Announces First Patient Randomized in a Phase 3 Clinical Study of Nefecon for IgA Nephropathy Patients in China

Everest Medicines Completes Enrollment of Phase 3 Clinical Trial of Xerava™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections in China

Everest Medicines Announces First Patient Dosed in a Phase 1b/2 Study of FGF401 in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors

Everest Medicines Announces Positive Results of In Vitro Study of Xerava™ (eravacycline) Against Human Mycoplasmas

Everest Medicines Completes US$310 Million Series C Financing

Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast

Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration to Initiate China Registration Study of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer

Everest Medicines Announces Approval of Xerava™ from the Health Science Authority in Singapore for the Treatment of Complicated Intra-Abdominal Infections